German government sources told Reuters on Sunday that the US administration was looking into how it could gain access to a potential vaccine being developed by a German firm, CureVac. "In this regard, the government is in intensive exchange with the company CureVac," she added. A German Economy Ministry spokeswoman also said Berlin "has a great interest" in producing vaccines in Germany and Europe. Welt am Sonntag said CureVac declined to comment. In the field of so-called mRNA therapeutics, CureVac competes with US biotech firm Moderna and German rival BioNTech, which Pfizer has identified as a potential collaboration partner.

Source: bd News24 March 15, 2020 13:52 UTC